Why You Don't Need to Cycle CJC-1295 or Tesamorelin
Most cycling advice you see online for CJC-1295 and Ipamorelin treats them as a single compound because they come packaged in the same vial. But they work through two completely separate receptor systems inside your pituitary gland, and those two systems behave very differently under continuous stimulation. Understanding why that matters changes how you think about cycling entirely.
Your pituitary is the master control center for growth hormone output, and it receives two distinct kinds of input signals. The first comes through something called GHRH receptors, which respond to growth hormone releasing hormone and function like a green light telling the pituitary to produce and release growth hormone. The second comes through something called ghrelin receptors, which respond to a different class of compounds called secretagogues and work more like an amplifier that turns up the volume on that same release signal. CJC-1295 and tesamorelin talk to the first system. Ipamorelin talks to the second. And those two systems desensitize in completely different ways, which is the whole point.
When you stimulate a receptor over and over again without giving it a rest, your body has a built-in protection mechanism. It pulls those receptors off the surface of the cell so they stop responding to the signal. This process is called something called beta-arrestin mediated internalization, which is essentially the cell dragging the receptor inside and away from the signal so it can no longer respond. The receptor is still there, just no longer available. And if you keep stimulating without giving the system a break, fewer and fewer receptors stay on the surface, and your response to the compound gets weaker over time.
This is exactly what happens with ghrelin receptor stimulation when you run Ipamorelin continuously. A 16-week human trial tracked this directly and found that growth hormone response declined approximately 45 percent from baseline by week 16 with continuous stimulation. That is nearly half the effect gone just from running it too long without a break. When subjects stopped for four weeks, the response came all the way back to where it started, meaning the internalization is reversible, but only if you actually give the receptors time to recover and return to the surface.
That is the scientific basis for the three months on, one month off cycle you hear recommended for Ipamorelin. The off period is not arbitrary, it is the window the receptors need to recover their surface density and restore your full response.
Now here is where CJC-1295 and tesamorelin fit into this picture. Both compounds work through GHRH receptors, not ghrelin receptors. And a key study using perifused rat pituitary cells confirmed that these two systems are functionally independent, meaning stimulating one does not desensitize the other, and each system has its own separate recovery dynamics. So the receptor problem that applies to Ipamorelin does not automatically apply to CJC or tesamorelin just because they are compounds that stimulate growth hormone.
The clinical data on tesamorelin makes this concrete. In the Phase 3 trials that led to FDA approval, patients received daily tesamorelin injections and IGF-1 levels held steady with no meaningful decline through the full 52 weeks of the trial. Not a dip at week 26. Not a gradual erosion. Stable across the entire year of continuous daily dosing. If GHRH receptor internalization were occurring at a clinically significant rate, you would expect to see that plateau or drop, and it is not there.
The likely reason comes down to the pharmacokinetics of tesamorelin itself. Tesamorelin has a half-life of roughly 26 to 38 minutes. When you inject it, you get a brief pulse of receptor stimulation and then the compound is cleared. Your GHRH receptors get a short signal and then have more than 23 hours before the next dose arrives. That recovery window appears to be enough to prevent meaningful receptor downregulation. The ghrelin receptor problem with Ipamorelin is partly a dosing frequency issue, and tesamorelin's short half-life gives the GHRH system the recovery time it needs between signals.
The data on ghrelin mimetics actually reinforces this point from the other direction. MK-677, which is an oral ghrelin receptor agonist, was studied continuously for two full years in healthy older adults and maintained IGF-1 and growth hormone elevation across that period without the catastrophic drop you might expect. This suggests ghrelin receptors can adapt to some level of chronic stimulation, or that the internalization seen at high doses in clinical peptide use follows different kinetics than that trial used. Either way, even the ghrelin receptor system has more nuance than a simple "run for three months and stop" rule implies, though the 45 percent decline data from the hexarelin trial is real and argues for a conservative cycling approach when running Ipamorelin specifically.
What this means practically is straightforward. If you are running CJC-1295 or tesamorelin by itself, there is no published human evidence that cycling is necessary. The receptor system they work through does not show the same internalization pattern, and the longest available human data shows no decline in response across a year of daily use. If you are running CJC with Ipamorelin together because they are compounded in the same vial, you cycle because of the Ipamorelin, not the CJC. The CJC is not driving the need for a break. The ghrelin receptor stimulation from the Ipamorelin is.
Most people who cycle both compounds together credit the break with keeping both compounds working, and they assume the cycling rule applies equally to everything in that vial. It does not. One half of the stack has a receptor desensitization problem. The other half, based on available evidence, does not.
The deeper lesson here is that "cycle your peptides" is not a universal rule about peptides. It is a specific rule about receptor biology, and the relevant question is always which receptor system you are working with and what the actual evidence says about how that system responds over time. The compound is not the unit of analysis. The receptor is.
References
- Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-143 — 16-week human trial showing 45% GH response decline with continuous ghrelin receptor stimulation, full recovery after 4 weeks off. Source
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin daily dosing for 26 weeks with sustained IGF-1 elevation. Source
- FDA Prescribing Information. EGRIFTA (tesamorelin). 2010/2025 — 52-week pooled Phase 3 data showing sustained IGF-1 and VAT reduction through week 52
- Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells. J Endocrinol. 1991;1291:11-19 — Proved GHRH and ghrelin receptor systems are independent with no cross-desensitization. Source
- Nass R et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;1499:601-611 — MK-677 ghrelin mimetic maintained GH/IGF-1 elevation for 2 years of continuous use. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.